ATE245032T1 - Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen - Google Patents

Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen

Info

Publication number
ATE245032T1
ATE245032T1 AT01910800T AT01910800T ATE245032T1 AT E245032 T1 ATE245032 T1 AT E245032T1 AT 01910800 T AT01910800 T AT 01910800T AT 01910800 T AT01910800 T AT 01910800T AT E245032 T1 ATE245032 T1 AT E245032T1
Authority
AT
Austria
Prior art keywords
neurotoxins
medications
thyroid disorders
treat thyroid
treat
Prior art date
Application number
AT01910800T
Other languages
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE245032T1 publication Critical patent/ATE245032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01910800T 2000-02-15 2001-02-15 Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen ATE245032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/504,538 US6524580B1 (en) 2000-02-15 2000-02-15 Method for treating thyroid disorders
PCT/US2001/004990 WO2001060396A2 (en) 2000-02-15 2001-02-15 Method for treating thyroid disorders

Publications (1)

Publication Number Publication Date
ATE245032T1 true ATE245032T1 (de) 2003-08-15

Family

ID=24006701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910800T ATE245032T1 (de) 2000-02-15 2001-02-15 Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen

Country Status (10)

Country Link
US (6) US6524580B1 (de)
EP (1) EP1253933B1 (de)
JP (2) JP2003530320A (de)
AR (1) AR027442A1 (de)
AT (1) ATE245032T1 (de)
AU (1) AU2001238369A1 (de)
DE (1) DE60100473T2 (de)
ES (1) ES2199209T3 (de)
TW (1) TWI283177B (de)
WO (1) WO2001060396A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US8563257B2 (en) 2000-03-30 2013-10-22 Diagnostic Hybrids, Inc. Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US8293879B2 (en) 2000-03-30 2012-10-23 Diagnostic Hybrids, Inc. Methods of using chimeric receptors to identify autoimmune disease
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7178059B2 (en) * 2003-05-07 2007-02-13 Egenera, Inc. Disaster recovery for processing resources using configurable deployment platform
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2005076785A2 (en) * 2003-12-19 2005-08-25 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
DE602005011458D1 (de) 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US7608275B2 (en) 2005-07-22 2009-10-27 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
RU2446791C2 (ru) * 2009-06-18 2012-04-10 Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" Способ этаноловой склеротерапии кистозно-трансформированных узлов щитовидной железы
EP2926757B1 (de) 2009-10-27 2023-01-25 Nuvaira, Inc. Freisetzungsvorrichtungen mit kühlbaren energieemissionsanordnungen
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9011323B2 (en) * 2010-10-08 2015-04-21 Invuity, Inc. Method and apparatus for soft tissue retraction
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
CA2869599C (en) 2012-04-13 2021-07-27 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
EP3758611B1 (de) 2018-02-26 2024-07-24 Ipsen Biopharm Limited Ultraschallgerät zur führung der injektion von nichttoxischer protease
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
CN117120033A (zh) 2021-03-30 2023-11-24 图拉维治疗股份有限公司 用于神经消融的方法和组合物
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5789397A (en) * 1991-01-08 1998-08-04 Bone Care International, Inc. Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
ES2107051T3 (es) 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
DE122009000066I2 (de) * 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69428813T2 (de) * 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
KR100544060B1 (ko) 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6022554A (en) 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6432723B1 (en) * 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6432623B1 (en) * 2001-04-27 2002-08-13 Eastman Kodak Company Method for processing a photographic element comprising a simultaneously coated protective overcoat

Also Published As

Publication number Publication date
EP1253933A2 (de) 2002-11-06
US6524580B1 (en) 2003-02-25
US6585970B1 (en) 2003-07-01
ES2199209T3 (es) 2004-02-16
JP2012207030A (ja) 2012-10-25
EP1253933B1 (de) 2003-07-16
US6447785B1 (en) 2002-09-10
WO2001060396A3 (en) 2002-03-14
AU2001238369A1 (en) 2001-08-27
DE60100473D1 (de) 2003-08-21
US6716427B1 (en) 2004-04-06
US6743424B1 (en) 2004-06-01
US6740321B1 (en) 2004-05-25
DE60100473T2 (de) 2004-04-15
WO2001060396A2 (en) 2001-08-23
JP2003530320A (ja) 2003-10-14
AR027442A1 (es) 2003-03-26
TWI283177B (en) 2007-07-01

Similar Documents

Publication Publication Date Title
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
ATE257013T1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
DE60232400D1 (de) Mittel zur linderung von hautreizungen
ATE338557T1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE50107445D1 (de) Verwendung von polyesteramiden zur stabilisierung von asphaltenen in rohöl
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
EE200100514A (et) LFA-1 ICAM-idega seondumise inhibiitorid ja nendekasutamine
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
ATE465728T1 (de) Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE69922873D1 (de) Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties